NKTR
NEKTAR THERAPEUTICS
NASDAQ · Healthcare · Biotechnology · US
$36.64
+2.40%Year over year
Reported trailing growth
- Revenue
- -27.2%
- EBITDA
- -53.8%
- EBIT
- -30.2%
- EPS
- +23.1%
- Free cash flow
- -25.8%
- Operating cash flow
- -26.4%
Forward estimates
Based on analyst estimates
- Revenue
- -27.2%
- EBITDA
- —
- EPS
- -66.6%
Three-year CAGR
- Revenue
- -15.7%
- EBITDA
- -58.0%
- EBIT
- -24.3%
- Net income
- -37.9%
- EPS
- -12.1%
- Free cash flow
- -17.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026